Tumor Dosimetry in 8 Patients with 13 Measurable Soft-Tissue Lesions
| Tumor 1 | Tumor 2 | Tumor 3 | |||||||
| MIBG/kg (MBq/kg) | Mass (g) | Dose (Gy) | Response | Mass (g) | Dose (Gy) | Response | Mass (g) | Dose (Gy) | Response |
| 326 | 7.85 | 273 | Stable disease | 13.1 | 53 | Stable disease | |||
| 377 | 5.6 | 49 | Stable disease | 7.9 | 63 | Stable disease | 11.5 | 63 | Stable disease |
| 426 | 58.6 | 378 | Stable disease | ||||||
| 488 | 9.6 | 43 | Stable disease | ||||||
| 551 | 11.7 | 43 | Stable disease | 8.5 | 46 | Stable disease | |||
| 614 | 175.0 | 26 | Stable disease | ||||||
| 648 | 39.0 | 48 | PD | ||||||
| 681 | 16.2 | 49 | Stable disease | 1.8 | 320 | Stable disease | |||
One patient with measurable soft-tissue lesion on CT had PR to NCA MIBG, but tumor dosimetry was not available on tumor.